Tokyo - Delayed Quote JPY

Japan Animal Referral Medical Center Co., Ltd. (6039.T)

2,666.00
+30.00
+(1.14%)
At close: 3:30:00 PM GMT+9
Loading Chart for 6039.T
  • Previous Close 2,636.00
  • Open 2,635.00
  • Bid 2,650.00 x --
  • Ask 2,678.00 x --
  • Day's Range 2,635.00 - 2,666.00
  • 52 Week Range 1,832.00 - 2,755.00
  • Volume 6,300
  • Avg. Volume 6,012
  • Market Cap (intraday) 6.891B
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) 14.85
  • EPS (TTM) 179.51
  • Earnings Date May 15, 2025
  • Forward Dividend & Yield 74.00 (2.81%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est --

Japan Animal Referral Medical Center Co., Ltd. owns and operates medical centers for animals in Japan. Its veterinary hospital provides advanced medical care service for dogs and cats. The company's medical center comprises cardiology, respiratory, urology, gastroenterology, oncology, neurology, orthopedics, ophthalmology, radiology and imaging, and anesthesiology departments. It also provides professional training services, such as clinical training and treatment; and conducts research and development projects, including genetic testing, immunotherapy, and regenerative medicine. Japan Animal Referral Medical Center Co., Ltd. was incorporated in 2005 and is headquartered in Kawasaki, Japan.

www.jarmec.co.jp

256

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 6039.T

View More

Performance Overview: 6039.T

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

6039.T
13.77%
Nikkei 225 (^N225)
4.43%

1-Year Return

6039.T
35.15%
Nikkei 225 (^N225)
0.59%

3-Year Return

6039.T
42.96%
Nikkei 225 (^N225)
44.27%

5-Year Return

6039.T
43.19%
Nikkei 225 (^N225)
91.46%

Compare To: 6039.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6039.T

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    6.81B

  • Enterprise Value

    9.70B

  • Trailing P/E

    14.69

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.46

  • Price/Book (mrq)

    1.76

  • Enterprise Value/Revenue

    2.00

  • Enterprise Value/EBITDA

    7.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.32%

  • Return on Assets (ttm)

    5.41%

  • Return on Equity (ttm)

    13.27%

  • Revenue (ttm)

    5.1B

  • Net Income Avi to Common (ttm)

    525.6M

  • Diluted EPS (ttm)

    179.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.03B

  • Total Debt/Equity (mrq)

    90.24%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 6039.T

View More

Company Insights: 6039.T

Research Reports: 6039.T

View More

People Also Watch